معرفی
Thomas Abrahamsson is a Professor at Linköping University, affiliated with the Faculty of Medicine and Health Sciences, within the Department of Biomedical and Clinical Sciences. He is part of the Division of Children's and Women's Health. His research focuses on neonatal care, particularly in preterm infants, addressing respiratory support, neurodevelopment, and nutritional interventions. He leads studies like the PICRINO trial and the N-forte trial, exploring neonatal outcomes and probiotic supplementation effects. His work integrates clinical research with public health strategies, such as centralization of preterm births to improve survival rates. Recent grants include a 30 million SEK award from the Swedish Heart Lung Foundation for heart, vascular, and lung disease research.
Research interests emphasize translational studies in neonatology, including respiratory disorders, neurodevelopmental assessment, and optimizing nutritional support for premature infants. His studies often involve large-scale clinical trials and observational cohorts to evaluate long-term health outcomes. Key areas include the role of human milk components in neurodevelopment and the impact of probiotics on gastrointestinal health in preterm neonates.
Grant activities highlight his focus on improving neonatal care through evidence-based practices. The Swedish Heart Lung Foundation grant supports projects aligned with his research on respiratory challenges in premature infants. He collaborates extensively with multidisciplinary teams, including clinicians and epidemiologists, to address critical gaps in neonatal healthcare.
His recent publications analyze trends in bronchopulmonary dysplasia, neurodevelopmental outcomes after probiotic use, and the efficacy of centralized neonatal care systems. These studies underscore his commitment to advancing both clinical practice and scientific understanding in neonatal medicine.
